Edwards Lifesciences Corporation
EW
Pozycja w akcjach
#489
Edwards Lifesciences Corporation is a global medical technology firm... Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Cena akcji
$86.46
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$49.82B
Zmiana (1 dzień)
-1.75%
Zmiana (1 rok)
15.84%
Kraj
US
Handel Edwards Lifesciences Corporation (EW)
Kategoria
Healthcare
Marża operacyjna dla Edwards Lifesciences Corporation (EW)
Marża operacyjna na dzień October 2026 TTM: 28.09%
Według najnowszych raportów finansowych i ceny akcji Edwards Lifesciences Corporation, bieżąca marża operacyjna (TTM) wynosi 28.09%. Na koniec 2024 wynosiła 25.35%.
Historia marży operacyjnej dla Edwards Lifesciences Corporation od 2000 do 2026
Marża operacyjna na koniec każdego roku
| Rok | Marża operacyjna | Zmień |
|---|---|---|
| 2026 (TTM) | 28.09% | -2,630.63% |
| 2025 | -1.11% | -104.38% |
| 2024 | 25.35% | -11.02% |
| 2023 | 28.49% | -9.93% |
| 2022 | 31.63% | 2.76% |
| 2021 | 30.78% | 4.16% |
| 2020 | 29.55% | 7.26% |
| 2019 | 27.55% | -6.10% |
| 2018 | 29.34% | -0.20% |
| 2017 | 29.40% | 6.83% |
| 2016 | 27.52% | 19.19% |
| 2015 | 23.09% | 10.11% |
| 2014 | 20.97% | -0.94% |
| 2013 | 21.17% | 1.39% |
| 2012 | 20.88% | 6.48% |
| 2011 | 19.61% | 0.46% |
| 2010 | 19.52% | 10.72% |
| 2009 | 17.63% | 4.38% |
| 2008 | 16.89% | 8.76% |
| 2007 | 15.53% | -1.52% |
| 2006 | 15.77% | -10.40% |
| 2005 | 17.60% | 6.15% |
| 2004 | 16.58% | 3.11% |
| 2003 | 16.08% | 117.30% |
| 2002 | 7.40% | 113.26% |
| 2001 | 3.47% | -70.64% |
| 2000 | 11.82% | 0.00% |
Marża operacyjna dla podobnych firm lub konkurentów
| Firma | Marża operacyjna | Różnica w marży operacyjnej | Kraj |
|---|---|---|---|
| 17.03% | -99.39% |
US
|
|
| 17.86% | -99.36% |
IE
|
|
| 22.03% | -99.22% |
US
|
|
| 21.46% | -99.24% |
US
|
|
| 0.00% | - |
DE
|
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.